浙江东亚药业股份有限公司第四届董事会第十三次会议决议公告

Group 1 - The fourth meeting of the board of directors of Zhejiang Dongya Pharmaceutical Co., Ltd. was held on December 25, 2025, with all 7 directors present [2][4] - The meeting approved the election of a director to represent the company in executing company affairs and the adjustment of the audit committee members [3][5] - The voting results for both resolutions were unanimous, with 7 votes in favor and no votes against or abstentions [4][6] Group 2 - Non-independent director Wang Sheng submitted his resignation due to adjustments in the company's governance structure, effective immediately upon delivery [9][10] - Wang Sheng was elected as the employee representative director during the employee representative assembly held on the same day, with a term aligned with the current board [9][11] - Wang Sheng holds 23,000 shares directly and 88,235 shares indirectly through an investment partnership, and his resignation does not affect the board's operational capacity [10] Group 3 - The board elected Chairman Chi Cheng as the director representing the company in executing company affairs, effective immediately [14][15] - The audit committee was adjusted to include members Wang Sheng, Feng Yan, and Cui Sunliang, with Feng Yan being appointed as the committee's convener [16][17] - The adjustments to the audit committee are in line with changes in the company's governance structure [16][18]